Home Newsfeeds Henry Schein Affirms FY22 Adj. EPS Guidance

Henry Schein Affirms FY22 Adj. EPS Guidance

Affirms full-year 2022 GAAP diluted EPS guidance range of $4.75 to $4.91, reflecting growth of 7% to 10% over full-year 2021 GAAP diluted EPS and growth

byBenzinga Newsdesk

August 2, 2022

1 minute read

Affirms full-year 2022 GAAP diluted EPS guidance range of $4.75 to $4.91, reflecting growth of 7% to 10% over full-year 2021 GAAP diluted EPS and growth of 5% to 9% over full-year 2021 non-GAAP diluted EPS

Vaccinex Reports Effect Of Pepinemab Treatment On New Biomarker Of Brain Inflammation In Neurodegenerative Diseases

By Benzinga Newsdesk

October 26, 9:31 AM

Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company, today reports novel findings for its lead product, pepinemab, in a highlighted podium presentation at the Clinical Trials on Alzheimer's Disease

VCNX

GlucoTrack Announces Early Accuracy Data For Its Implantable Continuous Glucose Monitor; Announces The Successful Completion Of Their First Preclinical Study Of The Implantable CBGM

By Benzinga Newsdesk

January 2, 1:34 PM

GlucoTrack, Inc. (NASDAQ:GCTK) ("GlucoTrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, provides, updates on

GCTK

Tricon Sees FY23 Core FFO Per Share $0.55-$0.58; Narrows Same Home Revenue Growth From 6%-7% To 6%-6.5%

By Benzinga Newsdesk

November 7, 9:19 PM

2023 Guidance UpdateThe Company updated its guidance for the current fiscal year, including reiterating the midpoint of Core FFO per share guidance and tightening the range of expected same home metrics. The Company also

TCN